Skip to main navigation
Skip Navigation
Landos Biopharma
  • - Landos - Corp Menu

  • About Us
    • Our Company
      • Management Team
      • Board of Directors
      • Clinical Advisory Board
    • Contact Us
  • Product Candidates
    • Clinical Pipeline
    • Preclinical Candidates
    • Clinical Trials
  • Science
    • LANCE Precision Medicine Platform
    • Immunometabolic Pathways
    • Publications
  • Investors/Media
    • Investor/Media Home
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investors/Media FAQs
  • Careers
    • Why Landos?
    • Open Positions
Identifying novel pathways at the interface of immunity and metabolism

Press Releases

11/21/23
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis
11/9/23
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
10/23/23
Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting
9/19/23
Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress
9/14/23
Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells
8/9/23
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
5/31/23
Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference
5/30/23
Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.
5/25/23
Landos Biopharma Announces 1-for-10 Reverse Stock Split
5/12/23
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 15

Investors/Media

Investor Relations

  • Investor/Media Home
  • Press Releases
  • Events & Presentations
  • Analyst Coverage
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investors/Media FAQs

- Landos - Investor Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
Landos Biopharma, Inc.
PO Box 11239
Blacksburg, VA 24062
info@landosbiopharma.com
(540) 218-2232

- Landos - Footer Menu

  • Site Map
  • Terms of Use
  • Privacy Policy

©2023 Landos Biopharma All Rights Reserved.